Table 3

Reasons for study termination

Reason for study termination Placebo (n (%)) Olsalazine (n (%))
Completed study75  (46.6)57  (34.1)
Relapse (CDAI)42 (26.1)40 (24.0)
Clinical relapse17 (10.6)15 (9.0)
Serious adverse events1 (0.6)2 (1.2)
Intolerable adverse events10 (6.2)33 (19.8)
Disallowed concomitant medication2 (1.2)4 (2.4)
Patient consent withdrawn3 (1.9)6 (3.6)
Other protocol violation3 (1.9)4 (2.4)
Other2 (1.2)1 (0.6)
Unknown1 (0.6)
Total reporting161 (100)167 (100)
  • CDAI, Crohn's disease activity index.